ALKEMPharmaceuticals
Alkem Laboratories Ltd — Cash Flow Statement
₹5299.00
-1.40%
Alkem Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 1.24K Cr | 1.69K Cr | 1.45K Cr | 772.14 Cr | — |
| Repayment Of Debt | -482.01 Cr | -520.89 Cr | — | -19.29 Cr | -38.74 Cr |
| Issuance Of Debt | 287.90 Cr | 40.00 Cr | — | 882.07 Cr | 178.42 Cr |
| Capital Expenditure | -675.62 Cr | -259.29 Cr | -232.91 Cr | -338.88 Cr | — |
| End Cash Position | -120.09 Cr | 66.31 Cr | 273.80 Cr | 232.18 Cr | — |
| Beginning Cash Position | 66.31 Cr | 273.80 Cr | 232.18 Cr | 174.22 Cr | — |
| Effect Of Exchange Rate Changes | 10.51 Cr | -2.05 Cr | 7.10 Cr | 2.50 Cr | — |
| Changes In Cash | -196.91 Cr | -205.44 Cr | 34.52 Cr | 55.46 Cr | — |
| Financing Cash Flow | -810.99 Cr | -1.15K Cr | -1.76K Cr | 379.57 Cr | — |
| Interest Paid Cff | -80.61 Cr | -91.31 Cr | -90.46 Cr | -40.13 Cr | — |
| Cash Dividends Paid | -504.62 Cr | -540.49 Cr | -529.52 Cr | -421.91 Cr | — |
| Net Issuance Payments Of Debt | -194.11 Cr | -480.89 Cr | -1.28K Cr | 862.78 Cr | — |
| Net Short Term Debt Issuance | -482.01 Cr | -520.89 Cr | -1.27K Cr | 882.07 Cr | — |
| Short Term Debt Payments | -482.01 Cr | -520.89 Cr | — | — | — |
| Net Long Term Debt Issuance | 287.90 Cr | 40.00 Cr | -9.50 Cr | -19.29 Cr | — |
| Long Term Debt Issuance | 287.90 Cr | 40.00 Cr | — | — | — |
| Investing Cash Flow | -1.30K Cr | -1.01K Cr | 112.84 Cr | -1.44K Cr | — |
| Interest Received Cfi | 347.71 Cr | 239.28 Cr | 146.91 Cr | 97.77 Cr | — |
| Dividends Received Cfi | 0.17 Cr | 0.19 Cr | 0.19 Cr | 0.19 Cr | — |
| Net Investment Purchase And Sale | -978.86 Cr | -1.06K Cr | 195.45 Cr | -1.21K Cr | — |
| Sale Of Investment | 4.72K Cr | 2.62K Cr | 412.98 Cr | — | — |
| Purchase Of Investment | -5.69K Cr | -3.68K Cr | -217.53 Cr | -1.21K Cr | — |
| Net Business Purchase And Sale | -33.00 Cr | 0.00 | — | — | — |
| Purchase Of Business | -33.00 Cr | 0.00 | — | — | — |
| Net PPE Purchase And Sale | -634.78 Cr | -186.81 Cr | -229.71 Cr | -327.98 Cr | — |
| Sale Of PPE | 40.84 Cr | 72.48 Cr | 3.20 Cr | 10.90 Cr | — |
| Purchase Of PPE | -675.62 Cr | -259.29 Cr | -232.91 Cr | -338.88 Cr | — |
| Operating Cash Flow | 1.91K Cr | 1.95K Cr | 1.68K Cr | 1.11K Cr | — |
| Taxes Refund Paid | -504.02 Cr | -406.94 Cr | -273.39 Cr | -396.90 Cr | — |
| Change In Working Capital | -213.97 Cr | -51.69 Cr | 326.77 Cr | -544.96 Cr | — |
| Change In Payable | 216.65 Cr | 525.28 Cr | 14.51 Cr | 334.49 Cr | — |
| Change In Inventory | -261.23 Cr | -73.40 Cr | 473.41 Cr | -673.14 Cr | — |
| Change In Receivables | -193.56 Cr | -357.10 Cr | -211.72 Cr | -265.33 Cr | — |
| Other Non Cash Items | -252.59 Cr | -165.34 Cr | -65.53 Cr | -86.32 Cr | — |
| Stock Based Compensation | 16.61 Cr | 18.94 Cr | 0.00 | 0.00 | — |
| Provisionand Write Offof Assets | 15.39 Cr | 84.20 Cr | 4.88 Cr | 2.78 Cr | — |
| Depreciation And Amortization | 357.16 Cr | 299.30 Cr | 310.42 Cr | 303.96 Cr | — |
| Amortization Cash Flow | 28.36 Cr | 31.78 Cr | 30.09 Cr | 51.89 Cr | — |
| Depreciation | 328.80 Cr | 267.52 Cr | 280.33 Cr | 252.07 Cr | — |
| Gain Loss On Investment Securities | -53.06 Cr | -15.36 Cr | -31.05 Cr | 3.33 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 11.16 Cr | 59.43 Cr | -11.88 Cr | -17.70 Cr | — |
| Gain Loss On Sale Of PPE | -4.60 Cr | 3.18 Cr | 12.36 Cr | 1.43 Cr | — |
| Net Income From Continuing Operations | 2.53K Cr | 2.02K Cr | 1.30K Cr | 1.84K Cr | — |
| Issuance Of Capital Stock | — | 0.00 | 161.48 Cr | 0.00 | — |
| Net Preferred Stock Issuance | — | 0.00 | 161.48 Cr | 0.00 | — |
| Preferred Stock Issuance | — | 0.00 | 161.48 Cr | 0.00 | — |
| Short Term Debt Issuance | — | — | — | 882.07 Cr | 178.42 Cr |
| Long Term Debt Payments | — | — | — | -19.29 Cr | -38.74 Cr |
| Net Intangibles Purchase And Sale | — | — | — | 0.00 | 35.10 Cr |
| Sale Of Intangibles | — | — | — | 0.00 | 35.10 Cr |
| Net Other Investing Changes | — | — | — | — | 0.84 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Alkem Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.